A human TREK-1/HEK cell line: a highly efficient screening tool for

A human TREK-1/HEK cell line: a
highly efficient screening tool for drug
development in neurological diseases
CONTEXT
Notre référence :
05287-01
Status des brevets
Not patented Biological
material
Inventeurs
Marc BORSOTTO
Catherine HEURTEAUX
TREK-1 potassium channels are involved in a number of physiopathological processes
such as neuroprotection, pain and depression. Molecules able to open or to block these
channels can be clinically important. Having a cell model for screening such molecules is
of particular interest.
TECHNICAL DESCRIPTION
The inventors have developed the first available cell line that constitutively expresses the
TREK-1 channel.
This cell line has been fully characterized with regards to the modulation properties of the
TREK-1 channel that is expressed. The results show that all its properties are retained: it
is opened by stretch, pH, polyunsaturated fatty acids and by the neuroprotective molecule,
riluzole and it is blocked by spadin or fluoxetine. In addition, the inventors have also
demonstrated that the h-TREK-1/HEK cell line is protected against ischemia by using the
oxygen-glucose deprivation model.
Status Commercial
MTA
Laboratoires
Institut de
Pharmacologie
Moléculaire et Cellulaire
, a CNRS and
University de Nice Sofia
Antipolis (UMR 6097),
in Valbonne, France.
Mots clés :
TREK-1 Cell line
Research tool
A) Typical pictures of cells observed in transmission and in fluorescence at round three of
cell culture. Functional channel activity was evaluated by current activation with 10 µM AA.
B) Typical pictures of cells observed in transmission and in fluorescence at round
fourteenth of cell culture. Functional channel activity was evaluated by current activation
with 10 µM AA.
C) Real time q-PCR. Levels of TREK-1 or sortilin expression were normalized with the
cyclophillin D expression.
INDUSTRIAL APPLICATIONS
High Throughput Screening on the TREK-1 target for drug discovery.
PUBLICATIONS
A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in
neurological diseases.
Moha ou Maati H et al. PLoS One. 2011;6(10):e25602.
For further information, please contact us (Ref 05287-01)
Powered by TCPDF (www.tcpdf.org)